Amir Mortazavi, MD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Professor

Research Program

Molecular Carcinogenesis and Chemoprevention

Research Interest

Cancer, Urinary Bladder Cancer, Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Weight Loss, Colorectal Cancer, Carcinoma, Renal Cell, Anorexia, Leukemia, Promyelocytic, Acute

Amir Mortazavi, MD, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where his research focuses on epigenetic modifications and experimental therapeutics for genitourinary cancers.

One of his recent research projects suggests that sorafenib, an oral multikinase inhibitor, could have off-target effects on cytokine-induced signal transduction in immune effector cells.

Dr. Mortazavi has co-authored many articles in well-respected publications, including Cancer Chemotherapy and Pharmacology, Journal of Immunology, Journal of Proteome Research and Journal of Magnetic Resonance Imaging.

Office Location

A441 Starling Loving Hall

320 W 10th Ave, Columbus, OH 43210

614-293-2886

614-293-7525

mortazavi.1@osu.edu

Publications

Cruciferous Vegetables, Isothiocyanates and Bladder Cancer Prevention.

Riedl KM, Mortazavi A, Clinton SK, Lucas CR, Abbaoui B

Mol Nutr Food Res in press 08/05/2018
Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial.

Simpson C, Clinton SK, Focht BC, Mortazavi A, Fairman CM, Buell J, Grainger E, Thomas-Ahner JM, Lucas AR, Monk JP

Ann Behav Med 52 412-428 04/19/2018
A Potential Role for Adjuvant Chemotherapy and Radiotherapy for Patients With High-Risk Bladder Cancer Treated With Cystectomy in the United States.

Mortazavi A, Lee CT, Diaz DA

JAMA Surg 153 e174592 01/17/2018
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58 2310-2318 10/01/2017
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S

Oncotarget 8 75822-75833 09/29/2017
Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Nguyen HT, Shah ZK, Mortazavi A, Pohar KS, Wei L, Jia G, Zynger DL, Knopp MV

Eur Radiol 27 2146-2152 05/01/2017
The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.

Abbaoui B, Telu KH, Lucas CR, Thomas-Ahner JM, Schwartz SJ, Clinton SK, Freitas MA, Mortazavi A

J Proteomics 156 94-103 03/06/2017
Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens.

Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, Sharp DS, Zynger DL

Urology 87 114-9 01/01/2016
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.

Mikhail S, Lustberg MB, Ruppert AS, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T

Cancer Chemother Pharmacol 76 1005-12 11/01/2015
Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

Shen HM, D'Souza AM, Green IF, Pohar KS, Mortazavi A, Zynger DL

Hum Pathol 46 1367-75 09/01/2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin Del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd, Martin Del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE

J Immunol 195 1995-2005 09/01/2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin Del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd, Martin Del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE

J Immunol 195 1995-2005 09/01/2015
Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.

Nguyen HT, Jia G, Shah ZK, Pohar K, Mortazavi A, Zynger DL, Wei L, Yang X, Clark D, Knopp MV

J Magn Reson Imaging 41 1374-82 05/01/2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.

Singh R, Harshman SW, Ruppert AS, Mortazavi A, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MR

Clin Proteomics 12 22 01/01/2015
Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

Clark D, Yang X, Knopp MV, Nguyen HT, Pohar KS, Jia G, Shah ZK, Mortazavi A, Zynger DL, Wei L

Invest Radiol 49 390-5 06/01/2014
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.

Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE 3rd, Tahiri S, Bhinder A, Clinton SK, Olencki T

J Immunother 37 180-6 04/01/2014
Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.

Singh R, Mortazavi A, Telu KH, Nagarajan P, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MR

Nucleic Acids Res 41 9284-95 11/01/2013

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Amir Mortazavi, MD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Cruciferous Vegetables, Isothiocyanates and Bladder Cancer Prevention.

Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial.

A Potential Role for Adjuvant Chemotherapy and Radiotherapy for Patients With High-Risk Bladder Cancer Treated With Cystectomy in the United States.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.

Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens.

Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.

Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.

Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.

Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.

Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Amir Mortazavi, MD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication